{"id":"ridaforolimus","rwe":[{"pmid":"41819443","year":"2026","title":"PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-β/PMEPA1 axis as a therapeutic strategy to overcome resistance.","finding":"","journal":"Biochemical pharmacology","studyType":"Clinical Study"},{"pmid":"41046532","year":"2025","title":"Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights.","finding":"","journal":"Drug development research","studyType":"Clinical Study"},{"pmid":"41018040","year":"2025","title":"Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.","finding":"","journal":"Therapeutic advances in medical oncology","studyType":"Clinical Study"},{"pmid":"39547969","year":"2024","title":"Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials.","finding":"","journal":"Journal of the American Heart Association","studyType":"Clinical Study"},{"pmid":"39411203","year":"2024","title":"Transcriptomic analysis reveals Streptococcus agalactiae activation of oncogenic pathways in cervical adenocarcinoma.","finding":"","journal":"Oncology letters","studyType":"Clinical Study"}],"tags":[{"label":"ridaforolimus","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Serine/threonine-protein kinase mTOR","category":"target"},{"label":"MTOR","category":"gene"},{"label":"DYRK1B","category":"gene"},{"label":"L01EG03","category":"atc"},{"label":"Active","category":"status"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"jenzyl","offLabel":[],"synonyms":["deforolimus","ridaforolimus","AP23573","MK-8669","jenzyl"],"timeline":[],"aiSummary":"Jenzyl (Ridaforolimus) is a small molecule inhibitor of the serine/threonine-protein kinase mTOR. It works by blocking the mTOR pathway, which is involved in cell growth and proliferation. Jenzyl is used to treat certain types of cancer, but its commercial status is unknown. The drug has a half-life of 46.3 hours, but its bioavailability and patent status are not publicly available. As a result, its availability as a generic medication is also unknown.","approvals":[],"brandName":"Jenzyl","ecosystem":[],"mechanism":{"target":"Dual specificity tyrosine-phosphorylation-regulated kinase 1B, Serine/threonine-protein kinase mTOR","targets":[{"gene":"MTOR","source":"DrugCentral","target":"Serine/threonine-protein kinase mTOR","protein":"Serine/threonine-protein kinase mTOR"},{"gene":"DYRK1B","source":"DrugCentral","target":"Dual specificity tyrosine-phosphorylation-regulated kinase 1B","protein":"Dual specificity tyrosine-phosphorylation-regulated kinase 1B"}],"modality":"Small Molecule","drugClass":"ridaforolimus","explanation":"Think of the mTOR pathway like a traffic light for cell growth. When mTOR is active, it's like the light is green, and the cell can grow and divide. Jenzyl works by flipping the light to red, stopping the cell from growing and dividing out of control.","oneSentence":"Jenzyl blocks the mTOR pathway, which is a key regulator of cell growth and division.","technicalDetail":"Jenzyl (Ridaforolimus) is a potent inhibitor of the mTOR kinase, specifically targeting the ATP-binding site and preventing the phosphorylation of downstream targets, including S6K1 and 4E-BP1."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4778","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=RIDAFOROLIMUS","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:32:22.531430","biosimilars":[],"competitors":[{"drugName":"temsirolimus","drugSlug":"temsirolimus","fdaApproval":"2007-05-30","patentExpiry":"Nov 10, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"everolimus","drugSlug":"everolimus","fdaApproval":"2009-03-30","patentExpiry":"May 1, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sirolimus","drugSlug":"sirolimus","fdaApproval":"1999-09-15","patentExpiry":"Oct 28, 2040","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ridaforolimus","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"temsirolimus","brandName":"temsirolimus","genericName":"temsirolimus","approvalYear":"2007","relationship":"same-class"},{"drugId":"everolimus","brandName":"everolimus","genericName":"everolimus","approvalYear":"2009","relationship":"same-class"},{"drugId":"sirolimus","brandName":"sirolimus","genericName":"sirolimus","approvalYear":"1999","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06071702","phase":"NA","title":"IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System","status":"SUSPENDED","sponsor":"Medinol Ltd.","startDate":"2025-08-07","conditions":["Coronary Stenosis","Coronary Artery Disease"],"enrollment":30,"completionDate":"2026-08-10"},{"nctId":"NCT06410313","phase":"NA","title":"First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease","status":"RECRUITING","sponsor":"Medinol Ltd.","startDate":"2024-08-15","conditions":["Superficial Femoral Artery Stenosis","Popliteal Artery Stenosis"],"enrollment":30,"completionDate":"2030-02-28"},{"nctId":"NCT05364697","phase":"NA","title":"IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medinol Ltd.","startDate":"2022-08-30","conditions":["Coronary Stenosis","Coronary Disease","Non-ST Elevated Myocardial Infarction","Cardiovascular Diseases"],"enrollment":60,"completionDate":"2029-12"},{"nctId":"NCT04761939","phase":"","title":"BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2020-12-31","conditions":["Coronary Stenosis","Coronary Disease","Myocardial Ischemia","Cardiovascular Diseases"],"enrollment":81,"completionDate":"2022-02-20"},{"nctId":"NCT00694083","phase":"PHASE1","title":"Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-06-10","conditions":["Neoplasm"],"enrollment":13,"completionDate":"2009-09-06"},{"nctId":"NCT01995487","phase":"NA","title":"Study of BioNIR Drug Eluting Stent System in Coronary Stenosis","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2014-01","conditions":["Coronary Artery Stenosis"],"enrollment":1919,"completionDate":"2020-11-30"},{"nctId":"NCT02828917","phase":"NA","title":"MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2017-01-16","conditions":["de Novo or Restenosis Lesions"],"enrollment":104,"completionDate":"2022-08-30"},{"nctId":"NCT00770185","phase":"PHASE2","title":"Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-11-13","conditions":["Endometrial Cancer"],"enrollment":35,"completionDate":"2015-02-13"},{"nctId":"NCT02736344","phase":"","title":"BIONICS - Pharmacokinetics (PK) Trial","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2016-04","conditions":["Heart Disease"],"enrollment":12,"completionDate":"2021-09"},{"nctId":"NCT03877848","phase":"","title":"EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2019-05-06","conditions":["Coronary Stenosis"],"enrollment":319,"completionDate":"2021-06-10"},{"nctId":"NCT01169532","phase":"PHASE1","title":"Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2010-10","conditions":["Lymphoma","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":16,"completionDate":"2014-03"},{"nctId":"NCT01995500","phase":"PHASE2","title":"Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2014-03-19","conditions":["Coronary Artery Stenosis"],"enrollment":300,"completionDate":"2020-06-17"},{"nctId":"NCT01212627","phase":"PHASE1","title":"Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer","status":"TERMINATED","sponsor":"Angela Taber MD","startDate":"2010-09","conditions":["Non-Small Cell Lung Cancer"],"enrollment":12,"completionDate":"2013-04"},{"nctId":"NCT03702608","phase":"NA","title":"BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2018-11-14","conditions":["Coronary Stenosis"],"enrollment":50,"completionDate":"2020-04-30"},{"nctId":"NCT02834806","phase":"NA","title":"BIONICS Israel Trial","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2016-09","conditions":["Stenosis"],"enrollment":58,"completionDate":"2017-12-16"},{"nctId":"NCT00874731","phase":"PHASE1","title":"A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-28","conditions":["Metastatic or Locally Advanced Cancer"],"enrollment":23,"completionDate":"2010-04-30"},{"nctId":"NCT01380184","phase":"PHASE1","title":"Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07-05","conditions":["Cancer, Advanced"],"enrollment":15,"completionDate":"2012-04-05"},{"nctId":"NCT01605396","phase":"PHASE2","title":"A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-04","conditions":["Breast Neoplasms"],"enrollment":80,"completionDate":"2018-03-15"},{"nctId":"NCT01431534","phase":"PHASE1","title":"A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-30","conditions":["Solid Tumors"],"enrollment":20,"completionDate":"2018-05-25"},{"nctId":"NCT00836927","phase":"PHASE2","title":"Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-01","conditions":["Advanced Cancers"],"enrollment":7,"completionDate":"2018-02-04"},{"nctId":"NCT01243762","phase":"PHASE1","title":"A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-22","conditions":["Neoplasms Malignant"],"enrollment":47,"completionDate":"2013-03-25"},{"nctId":"NCT01256268","phase":"PHASE1","title":"Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-06-13","conditions":["Endometrial Cancer","Ovarian Cancer"],"enrollment":24,"completionDate":"2017-08-03"},{"nctId":"NCT01234857","phase":"PHASE2","title":"A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-09-17","conditions":["Breast Cancer"],"enrollment":115,"completionDate":"2013-10-15"},{"nctId":"NCT01431547","phase":"PHASE1","title":"Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02","conditions":["Solid Tumors"],"enrollment":21,"completionDate":"2013-09"},{"nctId":"NCT00110188","phase":"PHASE2","title":"Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-05","conditions":["Prostate Cancer"],"enrollment":39,"completionDate":"2007-08"},{"nctId":"NCT00060645","phase":"PHASE1","title":"Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":["Tumors","Lymphoma","Multiple Myeloma"],"enrollment":33,"completionDate":"2009-02"},{"nctId":"NCT00736970","phase":"PHASE2","title":"Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":["Breast Cancer","Breast Neoplasms"],"enrollment":34,"completionDate":"2011-05"},{"nctId":"NCT00060632","phase":"PHASE1","title":"Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-04","conditions":["Tumors","Lymphoma","Multiple Myeloma"],"enrollment":46,"completionDate":"2005-10"},{"nctId":"NCT01295632","phase":"PHASE1","title":"Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02","conditions":["Advanced Cancer"],"enrollment":65,"completionDate":"2015-08"},{"nctId":"NCT00777959","phase":"PHASE2","title":"Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-10","conditions":["Prostate Cancer"],"enrollment":22,"completionDate":"2011-06"},{"nctId":"NCT00087451","phase":"PHASE1","title":"Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-07","conditions":["Malignant Glioma","Glioblastoma","Gliosarcoma"],"enrollment":11,"completionDate":"2005-11"},{"nctId":"NCT00086125","phase":"PHASE2","title":"Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":["Hematologic Malignancies","Leukemia","Myelodysplastic Syndromes","Myeloid Metaplasia","Lymphoma"],"enrollment":57,"completionDate":"2006-06"},{"nctId":"NCT00288431","phase":"PHASE1","title":"Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":["Cancer","Sarcoma"],"enrollment":37,"completionDate":"2008-07"},{"nctId":"NCT00739830","phase":"PHASE2","title":"Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":["Endometrial Cancer"],"enrollment":130,"completionDate":"2012-07"},{"nctId":"NCT01010672","phase":"PHASE2","title":"Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":["Sarcoma"],"enrollment":50,"completionDate":"2013-01"},{"nctId":"NCT01043887","phase":"PHASE1","title":"Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01","conditions":["Healthy Volunteers","Hepatic Insufficiency"],"enrollment":19,"completionDate":"2010-04"},{"nctId":"NCT01071304","phase":"PHASE1","title":"Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-03","conditions":["Relapsed or Refractory Advanced Cancer"],"enrollment":16,"completionDate":"2012-02"},{"nctId":"NCT00122343","phase":"PHASE2","title":"AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":["Endometrial Cancer"],"enrollment":45,"completionDate":"2008-01"},{"nctId":"NCT00704054","phase":"PHASE1","title":"A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":["Solid Tumors"],"enrollment":15,"completionDate":"2010-06"},{"nctId":"NCT00538239","phase":"PHASE3","title":"Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":["Metastatic Soft-Tissue Sarcomas","Metastatic Bone Sarcomas"],"enrollment":711,"completionDate":"2012-12"},{"nctId":"NCT00781846","phase":"PHASE1","title":"Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-10","conditions":["Solid Tumor"],"enrollment":17,"completionDate":"2010-02"},{"nctId":"NCT00093080","phase":"PHASE2","title":"Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10","conditions":["Leiomyosarcoma","Liposarcoma","Osteosarcoma","Sarcoma, Soft Tissue","Metastases"],"enrollment":216,"completionDate":"2008-11"},{"nctId":"NCT00112372","phase":"PHASE1","title":"Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-05","conditions":["Cancer"],"enrollment":147,"completionDate":"2009-03"},{"nctId":"NCT00730379","phase":"PHASE1","title":"A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":["Neoplasms"],"enrollment":87,"completionDate":"2010-11"},{"nctId":"NCT01220570","phase":"PHASE1","title":"The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-09","conditions":["Breast Cancer"],"enrollment":63,"completionDate":"2012-12"},{"nctId":"NCT00818675","phase":"PHASE2","title":"A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":["Non-Small Cell Lung Cancer"],"enrollment":80,"completionDate":"2012-08"},{"nctId":"NCT01296659","phase":"PHASE1","title":"Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-02","conditions":["Soft Tissue Sarcoma"],"enrollment":0,"completionDate":"2011-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"48Z35KB15K","CHEBI":"CHEBI:82677","INN_ID":"8822","UMLSCUI":"C2713007","ChEMBL_ID":"CHEMBL2103839","KEGG_DRUG":"D08900","DRUGBANK_ID":"DB06233","PUBCHEM_CID":"11520894","IUPHAR_LIGAND_ID":"7884","MESH_SUPPLEMENTAL_RECORD_UI":"C515074"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"46.3 hours","clearance":"1.1 mL/min/kg","volumeOfDistribution":"3.2 L/kg"},"publicationCount":111,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"L01EG03","allCodes":["L01EG03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 10","pmid":"41819443","title":"PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-β/PMEPA1 axis as a therapeutic strategy to overcome resistance.","journal":"Biochemical pharmacology"},{"date":"2025 Nov","pmid":"41046532","title":"Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights.","journal":"Drug development research"},{"date":"2025","pmid":"41018040","title":"Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.","journal":"Therapeutic advances in medical oncology"},{"date":"2024 Nov 19","pmid":"39547969","title":"Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials.","journal":"Journal of the American Heart Association"},{"date":"2024 Dec","pmid":"39411203","title":"Transcriptomic analysis reveals Streptococcus agalactiae activation of oncogenic pathways in cervical adenocarcinoma.","journal":"Oncology letters"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}